How to claim
- Pick a row and click claim. It opens the Suggest-an-edit issue form prefilled with the record and the gap; add the source URL, the missing links (ids of related objects) or the missing rows, and who you are.
- A maintainer checks the source, makes the edit and merges it. Nothing is edited directly: every change passes the same sourcing, safety and validation gate. If you can code, say so and you will be pointed at the file; pull requests reference the issue.
- Want to add a whole record? Propose it through New object: the form asks for the name, kind and one source, and a maintainer builds the validated record from it. Contributors are credited at /contributors/.
Counts by kind: 474 cancers, 20 fronts, 765 technologies, 1,674 targets, 1,088 drugs, 1,244 companies, 726 institutions, 109 pathways, 1,227 terms, 5,969 trials, 86 pairings, 38 roadmaps, 1,209 ideas, 139 collections, 1,604 people, 261 journals, 2,582 key papers, 54 bottlenecks, 174 years, 102 biomarkers.
Good first records
3728, audit of 2026-09-28Findings from the automated audit that a newcomer can fix with one source and no special knowledge of the codebase. Sized so you can pick by the time you have: 3693 S, 35 M, 0 L.
S: one field, one source, under an hourM: a few fields or links, an eveningL: a whole section or page, a weekend
- STrial- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic ColorecA year in the text is in the future; check whether the event happened and reword with a source. (mentions 2029 (looks forward-looking))claim
- STrial(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic MastocytosisA year in the text is in the future; check whether the event happened and reword with a source. (mentions 2032 (looks forward-looking))claim
- STrial(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaA year in the text is in the future; check whether the event happened and reword with a source. (mentions 2027 (looks forward-looking))claim
- STrial(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo A year in the text is in the future; check whether the event happened and reword with a source. (mentions 2027 (looks forward-looking))claim
- SKey paper[ 89 Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trialA year in the text is in the future; check whether the event happened and reword with a source. (mentions 2045)claim
- STrial[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsA year in the text is in the future; check whether the event happened and reword with a source. (mentions 2028 (looks forward-looking))claim
- STrial[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsA year in the text is in the future; check whether the event happened and reword with a source. (mentions 2028 (looks forward-looking))claim
- STrial125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal CancerA year in the text is in the future; check whether the event happened and reword with a source. (mentions 2027 (looks forward-looking))claim
- STrial16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal CancerA year in the text is in the future; check whether the event happened and reword with a source. (mentions 2028 (looks forward-looking))claim
- SYear1746 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1775 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1777 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- STrial177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsA year in the text is in the future; check whether the event happened and reword with a source. (mentions 2027 (looks forward-looking))claim
- SYear1806 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1809 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1812 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1814 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1823 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1832 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1834 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1838 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1840 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1842 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1844 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1845 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1855 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1857 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1859 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1869 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1870 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1872 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1873 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1874 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1875 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1878 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1879 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1880 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1881 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1882 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
- SYear1883 in oncologyAdd one primary source URL (label, publication, registry or guideline). (no external link or Wikipedia reference)claim
Showing 40 of 3728; the full list is in public/audit.json and on the audit page.